Breaking

U.S. Natural Gas Futures Drop Below $3 for First Time Since 2012
Tweet TWEET

Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With Successful Phase III Trials

Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With 
Successful Phase III Trials 
NEW YORK, NY -- (Marketwired) -- 05/22/13 --  Nuvilex, Inc. (OTCQB:
NVLX) is a diamond in the rough in the truest sense. Currently shares
of the Silver Spring, Maryland, biotechnology firm can be purchased
for around 0.15/share allowing investors to build an incredible
position in the company for what could be a blockbuster future. Don't
expect these great prices to last forever though. According to
Nuvilex's COO, Dr. Gerry Crabtree, the company expects to start its
pivotal Phase III trials in early 2014, so expect to start seeing
news being released by the company as each piece of the trial starts
to fall into place. Those who have any experience at all investing in
biotech and pharmaceutical companies know the excitement generated as
the news starts to unfold and the Phase III trials draw closer. 
Many can probably remember the days when Dendreon Corp. lit up
NASDAQ's boards with its first product, PROVENGE(R) (sipuleucel-T), a
cancer drug approved by the U.S. Food and Drug Administration (FDA)
in April 2010. By the end of the month, shares of Dendreon had
reached almost $60.00/share which was a far cry from the $2.60 the
company's shares hovered around while investors accumulated a
position just one year prior to FDA approval. 
No one is saying that Nuvilex is going to $60/share, but what could
be said is the company is ideally priced for investors who are
looking for that diamond in the rough, should the past be any
indication of the future. If Nuvilex's Phase III trials in advanced,
inoperable pancreatic cancer are successful, and we have every reason
at this point to expect that they will be, then a host of potentials
enter the picture for the future of the company.  
Stock House Group, a research and content development investment
relations firm, contends that the Phase III trials for Nuvilex will
be much like high school algebra where you knew the answer, but you
still had to show your work. It is our opinion that Nuvilex's cell
encapsulation technology is a "game-changer" and we feel the Phase
III trials will confirm what the technology has already confirmed in
two independent Phase II trials in advanced, inoperable pancreatic
cancer. 
In the data from those trials using encapsulated cells capable of
converting the anticancer drug ifosfamide into its "cancer-killing"
form, Median Survival Time and the One-Year Survival Rate were about
doubled as compared to historical data for Gemzar -- the current
standard and the only drug approved by the FDA as a single agent for
the treatment of advanced, inoperable pancreatic cancer. Now, it's up
to Nuvilex to "show its work" to the FDA and other regulatory
agencies. 
The list of potential accomplishments for Nuvilex is growing if the
company does, in fact, have successful Phase III trials. And, if even
one or two of those potential outcomes we've outlined below is
realized, it could prove to be a real "boon" for Nuvilex
shareholders.  
Continue reading this Article at www.stockhousegroup.com/features. 
About Stock House Group
 Stock House Group is a full service
Investment Relations firm specializing in Research, Content
Development and Awareness. The firm offers a platform for CEOs to
tell their story through the press with Feature Articles, Research
Reports, and CEO Interviews. At the same time, the company is
building a library of Research for Investors to become better
informed on small cap stocks. 
Stock House Group
www.stockhousegroup.com
info@stockhousegroup.com
(646) 397-4020 
 
 
Press spacebar to pause and continue. Press esc to stop.